On the Record · Syneos Health
Syneos Health acquisitions, on the record
The businesses Syneos Health bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
SynteractWord for word“We acquired the following companies during 2020: • Synteract, a full service CRO, focused on the emerging biopharmaceutical segment.” 10-K for 2020 | acquisition | during 2020 | — |
Illingworth Research GroupWord for word“• Illingworth Research Group™ (“Illingworth Research”), a leading provider of clinical research home health services.” 10-K for 2020 | acquisition | — | — |
contingent staffing businessWord for word“For the year ended December 31, 2020 , revenue attributable to our Clinical Solutions segment decreased compared to the prior year primarily due to the impacts of the COVID-19 pandemic, including the related decline in reimbursable out-of-pocket expenses, and the sale of the contingent staffing business during the second quarter.” 10-K for 2020 | divestiture | during the second quarter | — |
medication adherence businessWord for word“We sold our medication adherence business in November 2020, which will negatively impact our year over year revenue growth in 2021.” 10-K for 2020 | divestiture | in November 2020 | — |
Double Eagle Parent, Inc. (inVentiv)Word for word“We changed our name to Syneos Health, Inc. after o ur 2017 merger (the “Merger”) with Double Eagle Parent, Inc. (“inVentiv”), the parent company of inVentiv Health, Inc .” 10-K for 2020 | merger | 2017 | — |
StudyKIK Corporation (StudyKIK)Word for word“In addition to investing in our current technologies, we invested in new technology and data capabilities in 2021 through our acquisitions of StudyKIK Corporation (“StudyKIK”) and RxDataScience, Inc. (“RxDataScience”).” 10-K for 2021 | acquisition | 2021 | — |
RxDataScience, Inc. (RxDataScience)Word for word“In addition to investing in our current technologies, we invested in new technology and data capabilities in 2021 through our acquisitions of StudyKIK Corporation (“StudyKIK”) and RxDataScience, Inc. (“RxDataScience”).” 10-K for 2021 | acquisition | 2021 | — |
Illingworth ResearchWord for word“For the year ended December 3 1, 2020, we used $504.1 million in cash for investing activities, which primarily consisted of $456.5 million of cash paid for the acquisitions of Synteract and Illingworth Research.” 10-K for 2021 | acquisition | — | $456.5 million of cash paid for the acquisitions of Synteract and Illingworth Research |
Double Eagle Parent, Inc. (inVentiv), parent company of inVentiv Health, Inc.Word for word“We changed our name to Syneos Health, Inc. after o ur 2017 merger (the “Merger”) with Double Eagle Parent, Inc. (“inVentiv”), the parent company of inVentiv Health, Inc .” 10-K for 2021 | merger | 2017 | — |
inVentivWord for word“Our goodwill is principally related to the acquisition of inVentiv completed in August 2017.” 10-K for 2022 | acquisition | August 2017 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $0 | — |
| 2017-12-31 | $1.68 billion | $3.73 billion |
| 2018-12-31 | $90.9 million | — |
| 2019-12-31 | $712,000 | — |
| 2020-12-31 | $456.5 million | — |
| 2021-12-31 | $278.9 million | — |
| 2022-12-31 | $4.5 million | — |
Deal filings since 2016
- 2023-09-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-09-28 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-05-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-11-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-05-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-12-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-09-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-06-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-05-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-05-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-05-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Syneos Health’s annual reports (10-K for 2022, 10-K for 2021, 10-K for 2020) and the financial data it files with the SEC, as of 2023-02-16. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.